Skip to main content

FDA Updates

Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma

Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC

Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC

Vyxeos Now Indicated for Pediatric Patients with AML

Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma

FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma

Page 13 of 34
Results 121 - 130 of 331